Tinjauan Naratif Risiko dan Manfaat Penggunaan Kortikosteroid Sistemik pada Pasien PPOK dengan Pneumonia
Keywords:
benefit-risk assessment, copd, pneumonia, systemic corticosteroidsAbstract
Systemic corticosteroids are a standard treatment for acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). However, their use in COPD patients with concomitant pneumonia remains controversial because the balance between benefits and risks is unclear. This narrative review evaluated the benefits and risks of systemic corticosteroid therapy in COPD patients with pneumonia. Relevant articles published between 2017 and 2025 were identified through PubMed, Scopus, ScienceDirect, and Google Scholar. Eligible studies were analyzed and synthesized narratively to assess clinical outcomes. Systemic corticosteroids may provide benefits by reducing inflammation and improving respiratory symptoms. Nevertheless, most studies reported no significant improvement in mortality, treatment failure, intensive care unit admission, or rehospitalization rates. Conversely, corticosteroid use was associated with prolonged hospital stay, potential drug interactions, and immunosuppressive effects that may delay infection resolution. Overall, the available evidence suggests that the clinical benefits of systemic corticosteroids in COPD patients with concomitant pneumonia remain uncertain and should be weighed carefully against potential risks. Therefore, routine use is not recommended, and treatment decisions should be individualized according to the patient’s clinical condition.
References
Bai, L., Zhu, P., Pan, T., Liu, Y., Xu, Y., He, H., & Zhou, X. (2024). Association of systemic corticosteroid use with prognosis of patients with acute exacerbations of chronic obstructive pulmonary disease in the intensive care unit: A propensity score-matched cohort study. BMC Medicine, 22(1), 488. https://doi.org/10.1186/s12916-024-03705-4
Berliana, F., Prasetyawan, H. R., Indriani, N., & Sari, D. P. (2025). Studi Penggunaan Obat pada Pasien Penyakit Paru Obstruktif Kronik di RSUD R.T. Notopuro Sidoarjo. 4(2).
Ceccato, A., Russo, A., Barbeta, E., Oscanoa, P., Tiseo, G., Gabarrus, A., Di Giannatale, P., Nogas, S., Cilloniz, C., Menichetti, F., Ferrer, M., Niederman, M., Falcone, M., & Torres, A. (2021). Real-world corticosteroid use in severe pneumonia: A propensity-score-matched study. Critical Care, 25(1), 432. https://doi.org/10.1186/s13054-021-03840-x
Chronic obstructive pulmonary disease (COPD). (t.t.). Diambil 25 Juni 2026, dari https://www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-%28copd%29
Dao, D. T., Le, H. Y., Nguyen, M. H., Thi, T. D., Nguyen, X. D., Bui, T. T., Tran, T. H. T., Pham, V. L., Do, H. N., Horng, J.-T., Le, H. S., & Nguyen, D. T. (2024). Spectrum and antimicrobial resistance in acute exacerbation of chronic obstructive pulmonary disease with pneumonia: A cross-sectional prospective study from Vietnam. BMC Infectious Diseases, 24(1), 622. https://doi.org/10.1186/s12879-024-09515-6
DiPiro, J. T., Yee, G. C., Haines, S. T., Nolin, T. D., Ellingrod, V. L., & Posey, L. M. (2023). DiPiro’s Pharmacotheraphy A Pathophysiologic Approach (12 ed.). McGraw Hill LLC.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2025). Global Strategy for Prevention, Diagnosis and Management of COPD: 2025 Report. Global Initiative for Chronic Obstructive Lung Disease.
Melani, A. S., Croce, S., Cassai, L., Montuori, G., Fabbri, G., Messina, M., Viani, M., & Bargagli, E. (2023). Systemic Corticosteroids for Treating Respiratory Diseases: Less Is Better, but… When and How Is It Possible in Real Life? Pulmonary Therapy, 9(3), 329–344. https://doi.org/10.1007/s41030-023-00227-x
Papadopoulou, E., Bin Safar, S., Khalil, A., Hansel, J., Wang, R., Corlateanu, A., Kostikas, K., Tryfon, S., Vestbo, J., & Mathioudakis, A. G. (2024). Inhaled versus systemic corticosteroids for acute exacerbations of COPD: A systematic review and meta-analysis. European Respiratory Review, 33(171), 230151. https://doi.org/10.1183/16000617.0151-2023
Pitre, T., Abdali, D., Chaudhuri, D., Pastores, S. M., Nei, A. M., Annane, D., Rochwerg, B., & Zeraatkar, D. (2023). Corticosteroids in Community-Acquired Bacterial Pneumonia: A Systematic Review, Pairwise and Dose-Response Meta-Analysis. Journal of General Internal Medicine, 38(11), 2593–2606. https://doi.org/10.1007/s11606-023-08203-6
Pratt, A. J., Purssell, A., Zhang, T., Luks, V. P. J., Bauza, X., Mulpuru, S., Kirby, M., Aaron, S. D., & Cowan, J. (2023). Complexity in clinical diagnoses of acute exacerbation of chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 23(1), 298. https://doi.org/10.1186/s12890-023-02587-1
Purbosari, I., Affifah, A. N., & Sandhori, F. J. (2025). Studi Penggunaan Glukokortikoid Pada Pasien Penyakit Paru Obstruktif Kronik Di RSUD R.T. Notopuro Sidoarjo. JURNAL SAINS DAN KESEHATAN (J.SAINS.KES), 6(3), 96–107. https://doi.org/10.30872/jsk.v6i3.828.
Scholl, T., Kiser, T. H., & Vondracek, S. F. (2018). Evaluation of Systemic Corticosteroids in Patients With an Acute Exacerbation of COPD and a Diagnosis of Pneumonia. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 5(1), 57–65. https://doi.org/10.15326/jcopdf.5.1.2017.0157
Shiroshita, A., Anan, K., Takeshita, M., & Kataoka, Y. (2023). Systemic steroid therapy for pneumonic chronic obstructive pulmonary disease exacerbation: A retrospective cohort study. PLOS ONE, 18(9), e0290647. https://doi.org/10.1371/journal.pone.0290647
Wang, D., & Zhu, Y. (2024). The Complications of Corticosteroid for Patients with Community-acquired Pneumonia: A Systematic Review and Meta-Analysis. Alternative Therapies in Health and Medicine, 30(11), AT10003.
Williams, N. P., Ostridge, K., Devaster, J.-M., Kim, V., Coombs, N. A., Bourne, S., Clarke, S. C., Harden, S., Abbas, A., Aris, E., Lambert, C., Tuck, A., Williams, A., Wootton, S., Staples, K. J., & Wilkinson, T. M. A. (2018). Impact of radiologically stratified exacerbations: Insights into pneumonia aetiology in COPD. Respiratory Research, 19, 143. https://doi.org/10.1186/s12931-018-0842-8
Wu, J.-Y., Tsai, Y.-W., Hsu, W.-H., Liu, T.-H., Huang, P.-Y., Chuang, M.-H., Liu, M.-Y., & Lai, C.-C. (2023). Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials. Critical Care, 27(1), 274. https://doi.org/10.1186/s13054-023-04561-z
Zhao, Z., Lou, O., Wang, Y., Yin, R., Gong, C., Deng, F., Wu, E. C., Xie, J. Y., Wu, J., Ma, A., Guo, Y., & Xiong, W. T. (2023). Long- versus short-duration systemic corticosteroid regimens for acute exacerbations of COPD: A systematic review and meta-analysis of randomized trials and cohort studies. PLOS ONE, 18(12), e0296470. https://doi.org/10.1371/journal.pone.0296470
Zheng, F., & Wang, X. (2024). Effect of pneumonia on the outcomes of acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. BMC Pulmonary Medicine, 24(1), 496. https://doi.org/10.1186/s12890-024-03305-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Amalia Cahya, Armelia Allya Sandika, Febrian Faisal Aziz
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercial purposes.
- Adaptation — mixing, changing, and developing materials for any purpose, even commercial ones.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
